Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | MET | P08581 | 4/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 6/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30213799 | 0.91 | L3MBTL1 (0.48) | CYP2C19KMT2AMEN1METL3MBTL1 | |
| SCHEMBL28554876 | 0.91 | L3MBTL1 (0.48) | CYP2C19KMT2AMEN1METL3MBTL1 | |
| SCHEMBL29428770 | 0.85 | CYP2C19 (0.44) | CYP2C19KMT2AMEN1METHTR6 | |
| SCHEMBL29428833 | 0.85 | CYP2C19 (0.44) | CYP2C19KMT2AMEN1METHTR6 | |
| SCHEMBL2273205 | 0.85 | CYP2C19 (0.44) | CYP2C19KMT2AMEN1METHTR6 | |
| SCHEMBL25190824 | 0.85 | CYP2C19 (0.44) | CYP2C19KMT2AMEN1METHTR6 | |
| SCHEMBL17628727 | 0.85 | CYP2C19 (0.44) | CYP2C19KMT2AMEN1METHTR6 | |
| SCHEMBL28735217 | 0.85 | HTR6 (0.46) | CYP2C19KMT2AMEN1METHTR6 | |
| SCHEMBL12612708 | 0.84 | CYP2C19 (0.41) | CYP2C19KMT2AMEN1METL3MBTL1 | |
| SCHEMBL24166017 | 0.83 | CYP2C19 (0.42) | CYP2C19KMT2AMEN1METHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780840-B2 | Tricyclic urea compounds as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2023-10-10 | — | — | US | disclosed |
| EP-3584237-B1 | ALPHA ADRENERGIC RECEPTOR MODULATORS | ALLERGAN INC (US) | 2020-12-09 | — | — | EP | disclosed |
| US-20200039960-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2020-02-06 | — | — | US | disclosed |
| US-10426135-B2 | Methyl- and trifluromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof | PFIZER INC. (US) | 2019-10-01 | — | — | US | disclosed |
| EP-2486009-B1 | 2H-PYRROL-5-AMINE DERIVATIVES AS ALPHA ADRENERGIC RECEPTOR MODULATORS | ALLERGAN INC (US) | 2019-08-21 | — | — | EP | disclosed |
| US-20190150401-A1 | Methyl- and Trifluromethyl-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use Thereof | PFIZER INC. (US) | 2019-05-23 | — | — | US | disclosed |
| US-20190144429-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2019-05-16 | — | — | US | disclosed |
| US-10227346-B2 | Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use therof | PFIZER INC. (US) | 2019-03-12 | — | — | US | disclosed |
| EP-3428160-A1 | HETEROBICYCLOARYL RORC2 INHIBITORS AND METHODS OF USE THEREOF | Pfizer Inc (US) | 2019-01-16 | — | — | EP | disclosed |
| US-20180282304-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2018-10-04 | — | — | US | disclosed |
| US-8513419-B2 | N-(imidazolidin-2-ylidene)-heterocyclopenta[b]pyridine derivatives as modulators of alpha 2 adrenergic receptors | ALLERGAN, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513419-B2 | N-(imidazolidin-2-ylidene)-heterocyclopenta[b]pyridine derivatives as modulators of alpha 2 adrenergic receptors | ALLERGAN, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20130030014-A1 | N-(IMIDAZOLIDIN-2-YLIDENE)-HETEROCYCLOPENTA[b]PYRIDINE DERIVATIVES AS MODULATORS OF ALPHA 2 ADRENERGIC RECEPTORS | ALLERGAN, INC | 2013-01-31 | — | — | US | disclosed |
| US-20130030014-A1 | N-(IMIDAZOLIDIN-2-YLIDENE)-HETEROCYCLOPENTA[b]PYRIDINE DERIVATIVES AS MODULATORS OF ALPHA 2 ADRENERGIC RECEPTORS | ALLERGAN, INC | 2013-01-31 | — | — | US | disclosed |
| WO-2013015984-A1 | N-(IMIDAZOLIDIN-2-YLIDENE)-HETEROCYCLOPENTA[b]PYRIDINE DERIVATIVES AS MODULATORS OF ALPHA 2 ADRENERGIC RECEPTORS | ALLERGAN, INC. (US) | 2013-01-31 | — | — | WO | disclosed |
| WO-2013015984-A1 | N-(IMIDAZOLIDIN-2-YLIDENE)-HETEROCYCLOPENTA[b]PYRIDINE DERIVATIVES AS MODULATORS OF ALPHA 2 ADRENERGIC RECEPTORS | ALLERGAN, INC. (US) | 2013-01-31 | — | — | WO | disclosed |
| US-20130030014-A1 | N-(IMIDAZOLIDIN-2-YLIDENE)-HETEROCYCLOPENTA[b]PYRIDINE DERIVATIVES AS MODULATORS OF ALPHA 2 ADRENERGIC RECEPTORS | ALLERGAN, INC | 2013-01-31 | — | — | US | disclosed |
| US-20120208821-A1 | ALPHA ADRENERGIC RECEPTOR MODULATORS | ALLERGAN, INC (US) | 2012-08-16 | — | — | US | disclosed |
| EP-2486009-A1 | 2H-PYRROL-5-AMINE DERIVATIVES AS ALPHA ADRENERGIC RECEPTOR MODULATORS | Allergan, Inc. (US) | 2012-08-15 | — | — | EP | disclosed |
| WO-2011044229-A1 | 2H-PYRROL-5-AMINE DERIVATIVES AS ALPHA ADRENERGIC RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180282304-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | CYP2C19 471/4885KMT2A 1687/4885MEN1 3968/4885 |
| US-20200039960-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | CYP2C19 471/4885KMT2A 1687/4885MEN1 3968/4885 |
| US-20130030014-A1 | N-(IMIDAZOLIDIN-2-YLIDENE)-HETEROCYCLOPENTA[b]PYRIDINE DERIVATIVES AS MODULATORS OF ALPHA 2 ADRENERGIC RECEPTORS | ADRB2, ADRA2C, ADRA2A | CYP2C19 277/4885KMT2A 3304/4885MEN1 4100/4885 |
| US-10227346-B2 | Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use therof | RORC, RORB, RORA | CYP2C19 663/4885KMT2A 1396/4885MEN1 4017/4885 |
| US-11780840-B2 | Tricyclic urea compounds as JAK2 V617F inhibitors | JAK2, JAK1, JAK3 | CYP2C19 1141/4885KMT2A 727/4885MEN1 3542/4885 |
| US-20190144429-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | CYP2C19 471/4885KMT2A 1687/4885MEN1 3968/4885 |
| US-20120208821-A1 | ALPHA ADRENERGIC RECEPTOR MODULATORS | ADRB1, ADRB2, ADRA2C | CYP2C19 711/4885KMT2A 3759/4885MEN1 2178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.